187 related articles for article (PubMed ID: 23846931)
1. Update on novel therapies for pancreatic neuroendocrine tumors: 2013.
Dimou A; Syrigos KN; Saif MW
JOP; 2013 Jul; 14(4):377-80. PubMed ID: 23846931
[TBL] [Abstract][Full Text] [Related]
2. Update on novel therapies for pancreatic neuroendocrine tumors.
Oberstein PE; Saif MW
JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
4. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Oberstein PE; Saif MW
JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896
[TBL] [Abstract][Full Text] [Related]
5. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
6. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
7. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Hobday TJ; Qin R; Reidy-Lagunes D; Moore MJ; Strosberg J; Kaubisch A; Shah M; Kindler HL; Lenz HJ; Chen H; Erlichman C
J Clin Oncol; 2015 May; 33(14):1551-6. PubMed ID: 25488966
[TBL] [Abstract][Full Text] [Related]
9. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
10. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
11. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
Yao JC; Lombard-Bohas C; Baudin E; Kvols LK; Rougier P; Ruszniewski P; Hoosen S; St Peter J; Haas T; Lebwohl D; Van Cutsem E; Kulke MH; Hobday TJ; O'Dorisio TM; Shah MH; Cadiot G; Luppi G; Posey JA; Wiedenmann B
J Clin Oncol; 2010 Jan; 28(1):69-76. PubMed ID: 19933912
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
Khagi S; Saif MW
Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
[TBL] [Abstract][Full Text] [Related]
13. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: entering a new era.
Oberstein PE; Remotti H; Saif MW; Libutti SK
JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
[TBL] [Abstract][Full Text] [Related]
16. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):135-8. PubMed ID: 20208321
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
19. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
20. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]